BUSINESS● LOWSep 4 · Sep 4, 2026, 9:16 PM
Matinas BioPharma gets 2027 window to restore NYSE American listing compliance
Seeking Alpha Tech · north america
Matinas BioPharma has been granted until 2027 to regain compliance for its NYSE American listing. This reports an important regulatory development for the company's stock market status.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS28m agoTGSRTC launches ₹600 weekly bus pass for unlimited travel within Greater Hyderabad limitsThe HinduBUSINESS37m agoRetail investors pull back, but household stock demand remains strong: Goldman SachsSeeking Alpha Tech